Edition:
United States

People: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,091.00GBp
1 Dec 2016
Change (% chg)

-58.50p (-1.41%)
Prev Close
4,149.50p
Open
4,092.50p
Day's High
4,127.00p
Day's Low
4,052.00p
Volume
1,279,450
Avg. Vol
2,891,720
52-wk High
5,505.00p
52-wk Low
3,680.00p

Pangalos, Menelas 

Mr. Menelas Pangalos is the Executive Vice President - Innovative Medicines and Early Development of AstraZeneca PLC., since January 2013. He was appointed Executive Vice-President, IMED in January 2013 and leads AstraZeneca’s small molecule discovery research and early-stage development activities. Mene joined AstraZeneca from Pfizer, where he was Senior Vice-President and Chief Scientific Officer of Neuroscience Research. Previously, he held senior discovery and neuroscience roles at Wyeth and GSK. He completed his undergraduate degree in biochemistry at the Imperial College of Science and Technology, London and earned a doctorate in neurochemistry from the University of London. He is a Visiting Professor of Neuroscience at King’s College, London. In the UK, Mene serves on the Medical Research Council and the Innovation Board for the Association of the British Pharmaceutical Industry.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Leif Johansson

609,000

Pascal Soriot

8,397,000

Marc Dunoyer

5,955,000

Fiona Cicconi

--

Sean Bohen

--

Pam Cheng

--
As Of  30 Dec 2015